MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that, effective November 17, 2023, $2,965,000 of Secured Convertible Debentures were fully redeemed pursuant to exercise of the Conversion Rights by the Holders, resulting issuance of 59,300,000 common shares and 59,300,000 share purchase warrants exercisable at $0.20 until December 31, 2027..

安大略省密西沙加-（商业线）-MedX Health Corp.（“MedX”或“公司”）（TSX-V:MDX）很高兴地宣布，自2023年11月17日起，有担保可转换债券2965000美元根据持有人行使转换权而完全赎回，由此发行59300000股普通股和59300000股购买认股权证，可行使0.20美元，直至2027年12月31日。。

“This conversion of this Secured Debt sends a strong message of confidence in the future of MedX and continued support by the former debt-holders, and has eliminated of all the secured debt from the Company’s Balance Sheet. This positive step will greatly help the Company move forward with the ongoing roll-out of its SIAscopy® on DermSecure® telemedicine platform,” said Stephen Lockyer, CEO of MedX..

Stephen Lockyer说：“这种担保债务的转换传递了对MedX未来信心的强烈信息，并得到前债务持有人的持续支持，并消除了公司资产负债表中的所有担保债务。这一积极步骤将极大地帮助公司继续在DermSafe®远程医疗平台上推出SIAscopy®，MedX首席执行官。。

About MedX Health Corp.

关于MedX健康公司。

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility.

MedX总部设在加拿大安大略省，是一家专注于皮肤健康的领先医疗设备和软件公司，利用其SIAscopy®技术在DermSafe®远程医疗平台上实现SIAscopy®。SIAscopy®还嵌入其产品SIAMETRICS®，SIMSYS®和MoleMate®，MedX在其ISO 13485认证设施中生产。

SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.

SIAMETRICS®，SIMSYS®和MoleMate®包括手持设备，这些设备使用光和其汇出技术以无痛，无创的方式在可疑痣和病变下方最多2 mm处观察，然后使用其软件为医生和皮肤科医生创建实时图像，在几秒钟内评估所有类型的痣或病变。

These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com..

这些产品经加拿大卫生部，美国食品和药物管理局，治疗用品管理局和ConformitéEuropéenne批准，可在加拿大，美国，澳大利亚，新西兰，欧盟，巴西和土耳其使用。访问https://medxhealth.com..

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX Venture Exchange及其监管服务提供商（因为该术语在TSX Venture Exchange的政策中定义）均不对本版本的充分性或准确性承担责任。

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

本媒体发布可能包含前瞻性声明，反映公司目前对未来事件的期望。前瞻性陈述涉及风险和不确定性。